549 related articles for article (PubMed ID: 27884725)
41. The skeletal endocannabinoid system: clinical and experimental insights.
Raphael B; Gabet Y
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):237-45. PubMed ID: 26457774
[TBL] [Abstract][Full Text] [Related]
42. The endocannabinoid system: a general view and latest additions.
De Petrocellis L; Cascio MG; Di Marzo V
Br J Pharmacol; 2004 Mar; 141(5):765-74. PubMed ID: 14744801
[TBL] [Abstract][Full Text] [Related]
43. Endocannabinoid signaling in neurotoxicity and neuroprotection.
Pope C; Mechoulam R; Parsons L
Neurotoxicology; 2010 Sep; 31(5):562-71. PubMed ID: 19969019
[TBL] [Abstract][Full Text] [Related]
44. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology.
Ligresti A; De Petrocellis L; Di Marzo V
Physiol Rev; 2016 Oct; 96(4):1593-659. PubMed ID: 27630175
[TBL] [Abstract][Full Text] [Related]
45. The endocannabinoid system and cancer: therapeutic implication.
Guindon J; Hohmann AG
Br J Pharmacol; 2011 Aug; 163(7):1447-63. PubMed ID: 21410463
[TBL] [Abstract][Full Text] [Related]
46. Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids.
Wiley JL; Owens RA; Lichtman AH
Curr Top Behav Neurosci; 2018; 39():153-173. PubMed ID: 27278640
[TBL] [Abstract][Full Text] [Related]
47. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia.
Vigano D; Guidali C; Petrosino S; Realini N; Rubino T; Di Marzo V; Parolaro D
Int J Neuropsychopharmacol; 2009 Jun; 12(5):599-614. PubMed ID: 18789179
[TBL] [Abstract][Full Text] [Related]
48. Role of the endocannabinoid system in the development of tolerance to alcohol.
Basavarajappa BS; Hungund BL
Alcohol Alcohol; 2005; 40(1):15-24. PubMed ID: 15550443
[TBL] [Abstract][Full Text] [Related]
49. The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility.
Karasu T; Marczylo TH; Maccarrone M; Konje JC
Hum Reprod Update; 2011; 17(3):347-61. PubMed ID: 21227997
[TBL] [Abstract][Full Text] [Related]
50. [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?].
Saito VM; Wotjak CT; Moreira FA
Braz J Psychiatry; 2010 May; 32 Suppl 1():S7-14. PubMed ID: 20512266
[TBL] [Abstract][Full Text] [Related]
51. Signaling via CNS cannabinoid receptors.
Mackie K
Mol Cell Endocrinol; 2008 Apr; 286(1-2 Suppl 1):S60-5. PubMed ID: 18336996
[TBL] [Abstract][Full Text] [Related]
52. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
[TBL] [Abstract][Full Text] [Related]
53. The endocannabinoid system as a target for the treatment of neurodegenerative disease.
Scotter EL; Abood ME; Glass M
Br J Pharmacol; 2010 Jun; 160(3):480-98. PubMed ID: 20590559
[TBL] [Abstract][Full Text] [Related]
54. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
Fride E
Neuro Endocrinol Lett; 2004; 25(1-2):24-30. PubMed ID: 15159678
[TBL] [Abstract][Full Text] [Related]
55. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.
Burns TL; Ineck JR
Ann Pharmacother; 2006 Feb; 40(2):251-60. PubMed ID: 16449552
[TBL] [Abstract][Full Text] [Related]
56. Δ
Huerga-Gómez A; Aguado T; Sánchez-de la Torre A; Bernal-Chico A; Matute C; Mato S; Guzmán M; Galve-Roperh I; Palazuelos J
Glia; 2021 Mar; 69(3):532-545. PubMed ID: 32956517
[TBL] [Abstract][Full Text] [Related]
57. Endocannabinoid system in neurodegenerative disorders.
Basavarajappa BS; Shivakumar M; Joshi V; Subbanna S
J Neurochem; 2017 Sep; 142(5):624-648. PubMed ID: 28608560
[TBL] [Abstract][Full Text] [Related]
58. From endocannabinoid profiling to 'endocannabinoid therapeutics'.
Ligresti A; Petrosino S; Di Marzo V
Curr Opin Chem Biol; 2009 Jun; 13(3):321-31. PubMed ID: 19497779
[TBL] [Abstract][Full Text] [Related]
59. Unveiling the angiogenic effects of cannabinoids: Enhancers or inhibitors?
Maia J; Fonseca BM; Teixeira N; Correia-da-Silva G
Biochem Pharmacol; 2023 Sep; 215():115686. PubMed ID: 37463627
[TBL] [Abstract][Full Text] [Related]
60. Endocannabinoid overactivity and intestinal inflammation.
Di Marzo V; Izzo AA
Gut; 2006 Oct; 55(10):1373-6. PubMed ID: 16966693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
